Following publication of the appeal decision, the committee meeting scheduled for this topic on 21 February 2018 has been cancelled. This is to allow NICE sufficient time to review new evidence submitted by the company (Pfizer) prior to consideration by the appraisal committee. A new committee meeting date of 26 April 2018 is confirmed.